ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Status:
Completed
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
To seek preliminary evidence of antitumor activity (progression free survival) of Erlotinib
in combination with standard adjuvant chemoradiation and chemotherapy in patients with
resected adenocarcinoma of the pancreas.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins